key: cord-0745007-bpy0ed5c
authors: Maldonado, Genessis; Guerrero, Roberto; Intriago, Maria; Rios, Carlos
title: D-Dimer Trend in a Long-Term Rheumatoid Arthritis Patient with Tofacitinib Treatment and Recent COVID-19 Infection
date: 2021-07-05
journal: Revista Colombiana de Reumatología
DOI: 10.1016/j.rcreu.2021.06.003
sha: 325fef5f69f4422f0739e12483a0f6158b462984
doc_id: 745007
cord_uid: bpy0ed5c

The SARS-CoV-2 virus was first identified in December 2019, the infection was named COVID-19. The initial symptoms and evolution of the disease have been described over the past year. The virus has been shown to increase the risk of thromboembolic events due to the hypercoagulable state triggered by systemic endothelial inflammation. We present the case of a patient with a history of rheumatoid arthritis under prolonged treatment with tofacitinib, who presented COVID-19 and subsequently developed a hypercoagulable state of approximately 6 months’ duration. The possible association between viral infection and the use of tofacitinib is debated.

The SARS-CoV-2 virus responsible of the COVID-19 pandemic, presents mostly with constitutional symptoms such as fever, myalgias, headaches and respiratory symptoms, however, it has been evidenced that there is a procoagulant pattern with elevated fibrinogen, D-Dimer and prothrombin time. The pathophysiology under this mechanism is believed to be due to endothelial damage, which causes microvascular thrombi that impede homogeneous flow and produce a vascular shunt that is reflected in hypoxia and end-organ damage. Tang et al. evidenced that the use of anticoagulation with low molecular weight heparin in patients with and D-Dimer > 6-fold of upper limit of normal is associated with better prognosis and decreased mortality. 1 It is relevant to take into consideration diseases that are based on a chronic inflammatory state such as rheumatoid arthritis, since it can interfere with the management and development of both rheumatoid arthritis and co-infection with SARS-CoV-2. We present a possible association between tofacitinib therapy and increased D-Dimer in a patient with rheumatoid arthritis and COVID-19 infection. Further follow up showed an increase D-dimer trend for approximate 6 consecutive months (Figure 1 ). In the mist of this situation, it was decided to discontinue tofacitinib in late October and start tocilizumab 8mg/kg. Anticoagulation treatment was discontinued after 6 months and D-Dimer reduction was seen. During her last visit in December 2020, the patient denied polyarthralgia, further CDAI was 0 and D-Dimer levels were back to normal. The FORWARD study has a registry of approximately 530 patients with rheumatic diseases who were asked if they made any changes to their therapeutic regimen during these months of the COVID-19 pandemic, 14% reported having made changes on their own and 11% Based on medical advice, this demonstrated a perception of an increased risk of complications from COVID-19 secondary to the immunosuppressants indicated for their underlying disease. 8 However, it has been shown that patients with rheumatic diseases have a similar incidence of contagion and evolution of the disease compared to the general population. 9, 10 Because SARS-CoV-2 is a procoagulant risk factor and rheumatoid arthritis can be a causative agent as well, it is important to evaluate these patients, and if necessary, consider anticoagulant therapy.

The presence of rheumatic diseases such as rheumatoid arthritis is a risk factor for venous and / or arterial embolic events, however, the possible association with COVID-19 is uncertain. In addition, the added factor of the use of tofacitinib should be studied. In this case, the levels of D-Dimer decreased to normal after discontinuing tofacinitib, which makes a possible association between the drug and an increase in the hypercoagulable state in COVID-19 more evident. More studies are needed to confirm this possible relationship.

The authors confirm that the data supporting the findings of this study are available within the article.

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

JAK inhibitors in COVID-19: The need for vigilance regarding increased inherent thrombotic risk

Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and jak inhibitors

Thromboembolism with Janus Kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk?

Experiences of patients with rheumatic diseases in the united states during early days of the COVID-19 pandemic

How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 global rheumatology alliance physician-reported registry

The authors declare that they have no conflicts of interest.